Hematological Markers MPV, PLR, and NLR in Primary Versus Secondary Antiphospholipid Syndrome

Recruiting now

Conditions studied: Antiphospholipid Syndrome

In brief

Antiphospholipid syndrome is a thrombo-inflammatory autoimmune disorder with a complex antiphospholipid antibody-mediated pathogenesis, and high heterogeneity in clinical presentation and disease course. Clinical presentation in antiphospholipid syndrome includes venous and arterial thrombosis, pregnancy complications, and a broad range of microvascular and non-thrombotic manifestations

Key facts

Study ID

NCT07142239

Run by

New Valley University

People needed

150

Starts

2025-11-27

Expected to finish

2027-06-30

Last updated by the study team

2026-07-31

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Adults (age ≥18 years)
• Diagnosis of APS based on updated Sydney classification criteria confirmed by: Clinical history of thrombosis and/or pregnancy morbidity, Persistent presence (≥12 weeks) of antiphospholipid antibodies (aCL, anti-β2-glycoprotein I, and/or lupus anticoagulant)

You may not qualify if…

• Current infection or inflammatory condition unrelated to APS
• Hematological malignancies or other blood disorders
• Recent blood transfusion or platelet-altering medications other than APS treatments

Where it is running

• New Valley University — Al Khārjah, Kharga Oasis, Egypt (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.